Tests VC005 gel for mild to moderate atopic dermatitis in adults
Tests VC005 gel against a placebo gel in adults with atopic dermatitis.
Plain-language title generated from the registry record
Registry title: A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis
Key facts
- Where
- Hangzhou, ChinaSee the site
- Phase
- Phase 2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with mild to moderate atopic dermatitis (eczema) to test VC005 gel against a vehicle gel.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Atopic dermatitis meeting the Hanifin-Rajka criteria; the title says mild to moderate
Main reasons for not taking part
- Unstable atopic dermatitis within 2 weeks before baseline (improving on its own or getting worse fast)
- Skin lesions only on the hands or feet, with no past involvement of other typical areas
- Skin damage or changes at the treatment site that could affect evaluation (for example scars or tattoos)
- Other skin diseases such as psoriasis, acne, skin cancer or Netherton's syndrome
- History of malignant tumors, except certain fully removed cancers with no return for more than 5 years
Read by machine on 12 November 2026.
Where in China
- Hangzhou First People's HospitalHangzhou, ChinaContact: Liming WuTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Jiangsu vcare pharmaceutical technology co., LTD
- Trial code
- NCT07598383
- Record updated
- 7 July 2026
- Original description
This is a multicenter, randomized, double-blind, vehicle controlled phase II clinical study to evaluate the efficacy and safety of VC005 gel in adult subjects with mild to moderate atopic dermatitisRead full original descriptionShow less
A Multicenter, Randomized, Double-blind, Vehicle Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 Gel in Adult Subjects With Mild to Moderate Atopic Dermatitis
This is a multicenter, randomized, double-blind, vehicle controlled phase II clinical study to evaluate the efficacy and safety of VC005 gel in adult subjects with mild to moderate atopic dermatitis
Inclusion: Subjects fully understand this study, are able to follow the relevant procedures of the trial, voluntarily participate in the clinical trial, and sign the informed consent form (ICF); The age requirement for signing the ICF is 18 years old or above, with no gender restrictions; During screening, the diagnosis of atopic dermatitis should be met according to the Hanifin-Rajka criteria.
Exclusion: Patients judged by the investigator to have an unstable course of Atopic Dermatitis (AD) (spontaneous improvement or rapid deterioration) within 2 weeks before baseline; Patients with skin lesions limited to the hands or feet at screening and baseline, with no prior history of involvement in other typical areas (such as the face or flexural folds); Skin damage or abnormalities that may affect the evaluation of the investigational drug administration site (e.g., hyperpigmentation, large-area scars, tattoos, etc. at the affected site); Presence of skin diseases at screening and baseline that may affect the evaluation of the administration site, including but not limited to: psoriasis, acne, skin cancer, generalized erythroderma, Netherton's syndrome, etc; Patients with a history of malignant tumors, with the exception of: cervical carcinoma in situ, non-metastatic cutaneous squamous cell carcinoma or basal cell carcinoma, or non-metastatic papillary thyroid carcinoma that have been completely resected with no evidence of recurrence for more than 5 years of survival.